



Healthcare Weekly News and Deals –May 25th, 2026

🇺🇸 Happy Memorial Day! 🇺🇸

1. [Oura Inc. \(ŌURA\) submits confidential draft Form S-1 to the SEC for a proposed initial public offering of its common stock.](#)

San Francisco-based Oura Inc., the smart-ring maker behind the Oura Ring, has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range have not yet been determined, with the IPO expected after the SEC completes its review. Oura was valued at \$11 billion in October 2025 following a \$900 million Series E and is projected to generate roughly \$2 billion in 2026 revenue. The company supports over 1,200 wellness and medical partners. [\(Link\)](#)

2. [Medtronic \(NYSE: MDT\) to Acquire SPR Therapeutics for \\$650 Million](#)

Medtronic plc has agreed to acquire SPR Therapeutics, a pioneer in minimally invasive peripheral nerve stimulation (PNS) technology, in an all-cash transaction valued at \$650 million. The deal brings in SPR's FDA-cleared SPRINT PNS System, a temporary, non-opioid solution for chronic pain that has demonstrated strong clinical outcomes with lower risk compared to permanent implants. For Medtronic, this bolsters its neuromodulation portfolio and accelerates its shift toward less invasive, drug-free pain management therapies amid growing demand for opioid alternatives. The acquisition is expected to close in the first half of Medtronic's fiscal 2027 and should be immediately accretive to earnings. [\(Link\)](#)

3. [Eli Lilly and Company \(NYSE: LLY\) Acquires Engage Bio to Accelerate Development of Non-Viral Genetic Medicines](#)

Eli Lilly and Company has acquired Engage Bio, a preclinical biotechnology company focused on non-viral delivery platforms for genetic medicines. The deal provides Lilly with proprietary technology aimed at improving the safety and efficacy of gene editing and RNA-based therapies. Engage Bio's platform is designed to overcome key limitations of current viral vector approaches, potentially enabling broader application of genetic medicines. This acquisition reinforces Lilly's commitment to building leadership in next-generation genetic medicine platforms. [\(Link\)](#)

4. [BrainsWay Ltd. \(NASDAQ: BWAY; TASE: BWAY\) invests \\$1.5M for a minority stake in Hopemark Health, operated by Advanced Psychiatric Management LLC under parent APS Innovations LLC.](#)

Burlington, Mass.-based BrainsWay Ltd. (NASDAQ: BWAY; TASE: BWAY) has entered a strategic equity financing agreement with APS Innovations LLC, the parent of Advanced Psychiatric Management LLC, which operates Chicago-area mental health clinics under the Hopemark Health brand. BrainsWay is investing \$1.5 million for a minority position via a preferred, annually compounding security, with the potential for an additional \$1.5 million through milestone-based investments and a redemption mechanism. CEO Hadar Levy described the deal as part of BrainsWay's strategy to partner with growth-oriented clinical platforms and expand access to interventional psychiatry solutions including Deep TMS. BrainsWay is valued at roughly \$606 million. [\(Link\)](#)

Healthcare Weekly News and Deals – May 25th, 2026

5. **QT Imaging Holdings, Inc. (NASDAQ: QTI) closes a \$10M underwritten public offering with both existing and new investors participating.**

Novato, Calif.-based QT Imaging Holdings, Inc. (NASDAQ: QTI) has completed an underwritten public offering of 2,000,000 shares of common stock or pre-funded warrants, generating gross proceeds of approximately \$10 million. The offering was priced at \$5.00 per share, with pre-funded warrants at \$4.9999, and saw participation from both existing and new investors. Net proceeds will be used for working capital and general corporate purposes. QTI shares had declined 24% over the week prior to closing, trading at \$5.49 with a market capitalization of \$65.63 million. QT Imaging develops radiation-free, ultrasound-based breast imaging technology and recently posted strong Q1 2026 revenue growth. ([Link](#))

6. **Innovaccer Inc. acquires CaduceusHealth (reported at \$66M) to build out its agentic revenue cycle management platform.**

San Francisco-based healthcare AI company Innovaccer Inc. has acquired CaduceusHealth, a nationally recognized revenue cycle management services provider, in a reported \$66 million asset deal — Innovaccer's fifth strategic acquisition. Founded in 1997, CaduceusHealth manages billing, claims, and denial resolution for nearly 4,000 providers and handles \$5 billion in gross patient charges annually across every major EHR. The transaction expands Innovaccer's Flow suite into full-stack RCM capabilities, unifying scheduling, patient engagement, and end-to-end revenue cycle workflows for ambulatory care providers. The integrated platform leverages Innovaccer's Gravity AI infrastructure to address the nearly \$20 billion lost annually to avoidable denials. ([Link](#))

7. **Nexalin Technology, Inc. (NASDAQ: NXL) acquires PONM, Inc. from GreenLight Ventures, LLC for \$1.3M in stock.**

Houston-based Nexalin Technology, Inc. (NASDAQ: NXL) has closed the acquisition of PONM, Inc. from GreenLight Ventures, LLC for \$1.3 million payable in Nexalin common stock issued across four tranches, with 959,016 shares delivered at closing. PONM is the AI-integrated digital health platform powering Nexalin's HALO Clarity neurostimulation program and Nexalin NeuroCare virtual clinic, already deployed at UC San Diego. Nexalin gains ownership of PONM and an exclusive license to proprietary software for remote patient monitoring, EHR functionality, and virtual-clinic management. GreenLight becomes a significant Nexalin equity holder and continues engineering, cybersecurity, and regulatory support under a 24-month collaboration agreement. ([Link](#))

8. **GHO Capital and CBC Group Merge to Create \$21 Billion Global Healthcare Investment Platform**

GHO Capital and CBC Group have completed a transformational merger to form one of the world's largest dedicated healthcare private equity firms with over \$21 billion in assets under management. The combined platform brings together GHO's European mid-market expertise with CBC's strong Asia-Pacific presence and deep sector relationships. The merger significantly enhances the firm's ability to pursue larger transactions and cross-border opportunities across healthcare services, biotech, and medtech. For limited partners, this creates a truly global healthcare investor with greater scale, sourcing advantages, and operational resources. ([Link](#))

9. Grundium (backed by EW Healthcare Partners) Acquires Visiopharm to Create Integrated Precision Pathology Platform

Grundium Oy, backed by EW Healthcare Partners, has acquired Visiopharm A/S, a leader in AI-powered image analysis software for digital pathology. The strategic combination merges Grundium's high-quality digital slide scanners with Visiopharm's advanced AI algorithms for automated tissue analysis and biomarker quantification. The deal creates a comprehensive end-to-end precision pathology solution that improves diagnostic accuracy, reduces turnaround times, and supports pathologists facing increasing workloads. For investors, this positions the combined platform to capture significant share in the rapidly growing computational pathology market driven by oncology and personalized medicine. [\(Link\)](#)

10. Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for Biopharma and Healthcare

Cohere has acquired Reliant AI, a biopharma-specialized AI company with operations in Montreal and Berlin. The transaction strengthens Cohere's vertical AI capabilities in regulated industries by integrating Reliant's domain-specific models optimized for clinical, regulatory, and research workflows. This move enhances Cohere's ability to deliver sovereign, privacy-compliant AI solutions for large pharmaceutical and healthcare enterprises. The acquisition underscores the accelerating trend of big tech players deepening vertical specialization to address the unique data governance and compliance requirements of life sciences. [\(Link\)](#) [\(Link\)](#)

11. Pillr Health (backed by Water Street Healthcare Partners) acquires CaptureRx for undisclosed terms to expand its 340B pharmacy solutions platform.

Boca Raton, Fla.-based Pillr Health — a 340B-focused pharmacy optimization platform recently acquired by Water Street Healthcare Partners from Renovus Capital Partners — has acquired San Antonio-based CaptureRx, a 340B technology and services organization. Terms were not disclosed. The transaction extends Pillr Health's reach to more than 500 hospitals, health systems, and federally qualified health centers nationwide and consolidates CaptureRx's 20-plus years of 340B expertise into Pillr's integrated platform spanning split billing, contract pharmacy administration, entity-owned pharmacy management, referral capture, and compliance support. CEO Skip Devanny will lead the combined organization as covered entities face mounting 340B regulatory and compliance pressure. [\(Link\)](#)

12. \$200M Merger of Dominion Aesthetic Technologies Inc. and BellaMia Technologies Inc. Creates New Laser Device Leader

Dominion Aesthetic Technologies and BellaMia Technologies have merged in a transaction valued at approximately \$200 million to create a leading player in medical aesthetics laser devices. The combined company brings together complementary portfolios of energy-based devices for body contouring, skin rejuvenation, and hair removal. The merger is expected to deliver meaningful revenue and cost synergies while accelerating innovation and international expansion. Backed by strong private equity sponsorship, the new entity is well-positioned to capitalize on the continued growth of the global aesthetic medicine market. [\(Link\)](#)

Healthcare Weekly News and Deals – May 25th, 2026

13. Endologix Acquires Pounce Thrombectomy System to Expand Vascular Intervention Portfolio

Endologix has acquired the Pounce Thrombectomy System, a novel mechanical thrombectomy technology for arterial clot removal. The deal expands Endologix's peripheral vascular portfolio beyond its core AAA stent graft business into the high-growth thrombectomy segment. Pounce offers a differentiated, low-profile solution for rapid clot extraction in acute limb ischemia cases. The acquisition supports Endologix's strategy to build a more diversified vascular intervention platform and improve patient outcomes in peripheral arterial disease. [\(Link\)](#)

14. Everis Medical Announces Acquisition of Hood Laboratories to Expand Head, Neck, and Airway Management Portfolio

Everis Medical has acquired Hood Laboratories, a specialist in airway management and head/neck surgical products. The transaction broadens Everis' product offering in otolaryngology and anesthesia with Hood's established portfolio of silicone stents, tracheostomy tubes, and related airway devices. This strategic add-on enhances Everis' position in niche ENT and airway markets while providing cross-selling opportunities across its existing customer base. The acquisition reflects continued consolidation in the fragmented medical device specialty markets. [\(Link\)](#)

15. Lexitas Pharma Services Acquires Erie Retina Research and Element Erie

Lexitas Pharma Services, a leading ophthalmology-focused contract research organization (CRO), has acquired Erie Retina Research (CASExERIE) and Element Erie. The transaction significantly expands Lexitas' clinical trial capabilities in retinal diseases and strengthens its presence in the Midwest. The acquired sites bring established investigator networks, experienced staff, and a robust pipeline of ongoing retinal studies. This acquisition bolsters Lexitas' position as a premier ophthalmology CRO amid rising demand for specialized expertise in macular degeneration, diabetic retinopathy, and other vision-threatening conditions. [\(Link\)](#)

16. Midlothian Dermatology Joins Epiphany Dermatology

Epiphany Dermatology, a leading physician-led dermatology practice platform, has acquired Midlothian Dermatology in Texas. The transaction expands Epiphany's footprint in the Dallas-Fort Worth metro area and adds a well-established clinical team with strong patient loyalty. This continues Epiphany's disciplined roll-up strategy in high-growth dermatology markets, supported by robust demand for medical, surgical, and cosmetic services. The deal reflects ongoing consolidation in the dermatology sector as independent practices seek scale, operational support, and capital for expansion. [\(Link\)](#)

17. Ballantyne Plastic Surgery acquired by Alexis Miller and Gen3 Innovations Lab Aesthetics and Wellness Group, with capital partnership from New Majority Capital.

Charlotte, N.C.-based Ballantyne Plastic Surgery, a 30-plus-year aesthetic practice founded by Thomas G. Liszka, M.D., has been acquired by Alexis Miller and Gen3 Innovations Lab Aesthetics and Wellness Group, with capital partnership from impact-focused investor New Majority Capital. Gen3 is an entrepreneurship-through-acquisition (ETA) search-fund vehicle targeting cash-flowing businesses with enterprise value between \$5 million and \$20 million. Miller, who holds an MBA from Chicago Booth and previously held roles at TikTok, Facebook, and Adobe, will serve as principal and managing partner. The acquisition continues the practice's offerings of surgical and non-surgical aesthetic procedures in the Charlotte community. [\(Link\)](#)

Healthcare Weekly News and Deals – May 25th, 2026

18. Clutch Health acquires Perx Health's U.S. operations for undisclosed terms, marking its second healthcare acquisition.

Philadelphia-based Clutch, an AI-powered retention, loyalty and engagement platform serving commerce and healthcare, has acquired the U.S. operations of digital health engagement company Perx Health. Terms were not disclosed. This is Clutch's second healthcare acquisition, following its 2025 acquisition of Reciprocity Health. Perx's behavioral-science-driven mobile platform — used by major U.S. health plans and provider organizations — drives medication adherence, treatment plan completion, and chronic condition self-management through gamification and personalized incentives. Perx CEO Scott Taylor will operate within Clutch Health reporting to CEO Craig Hauben, combining Perx's engagement engine with Reciprocity's incentive science and Clutch's AI and data platform. [\(Link\)](#)

19. Predict Health acquires the Insightin Health platform (inGAGE™) for undisclosed terms to build a unified AI solution for payer intelligence and member engagement.

Arlington, Va.-based Predict Health has acquired the Insightin Health platform, an AI-powered healthcare engagement and orchestration solution serving Medicare Advantage, Medicaid, DSNP, ACA, and Commercial health plans. Financial terms were not disclosed. The combined platform will support health plans serving more than 3 million covered lives across 25 states and powers millions of member interactions annually. Predict Health leverages over 800 million healthcare and consumer data records and 300 million-plus member profiles, while the acquired inGAGE™ platform adds real-time journey orchestration, next-best-action decisioning, and omnichannel outreach across phone, text, IVR, email, direct mail, and digital channels. [\(Link\)](#)

20. InSphero AG Acquires PhenoVista Biosciences Inc. to Expand Advanced 3D Cell-based Assay Capabilities

InSphero AG has acquired PhenoVista Biosciences, a provider of advanced 3D cell-based assay services and imaging solutions. The transaction significantly strengthens InSphero's position in the rapidly growing 3D microtissue and organoid market for drug discovery and toxicology. PhenoVista brings proprietary assay development expertise and high-content imaging capabilities that complement InSphero's spheroid and organoid platform technologies. The acquisition enhances InSphero's ability to support pharmaceutical clients with more predictive, human-relevant preclinical models. [\(Link\)](#)

Venture Deals and Other

1. **Century Health raises \$5M Seed led by Origin Ventures with participation from InnovateHealth Ventures, 25madison, Next Play Ventures, 2048 Ventures, Alumni Ventures, and angel investor Zorba Lieberman.**

Century Health, a New York-based healthcare AI company, has closed an oversubscribed \$5 million Seed round. The financing was led by Origin Ventures, the Chicago-based early-stage venture firm focused on the "digital native economy," with participation from InnovateHealth Ventures, 25madison, Next Play Ventures, 2048 Ventures, Alumni Ventures, and strategic angel investors including Zorba Lieberman alongside clinician angels. The capital will fund expansion of partnerships with pharmaceutical and life sciences companies, growth of Century's specialty provider data network, and enhancements to its AI-powered CHARM platform that converts unstructured EHR data into research-ready real-world evidence across neurology, nephrology, ophthalmology, and other specialties. ([Link](#))

2. **Commure raises \$70M at a \$7B post-money valuation led by General Catalyst with participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis.**

Mountain View-based Commure, the AI platform for healthcare operations, has banked \$70 million in fresh financing at a \$7 billion post-money valuation, taking total funding to \$750 million. General Catalyst led the round with participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis. The company, which merged with Athelas in 2023, deploys agentic AI and ambient workflow tools across more than 500 healthcare organizations and 3,000-plus care sites, including over 130 of the country's largest health systems such as Tenet Healthcare and HCA Healthcare. Proceeds will scale its revenue cycle and practice management platform, enhance agentic AI infrastructure, and expand globally. ([Link](#))

3. **CVRD Health raises \$5M Seed led by Upfront Ventures with participation from Waterline Ventures and Distributed Ventures.**

CVRD Health has closed a \$5 million Seed round led by Upfront Ventures, with participation from Waterline Ventures and Distributed Ventures. Upfront's general partner Kevin Zhang highlighted CVRD's positioning in the underserved government contracting market, where federal contracting exceeds \$773 billion annually. The proceeds will fund platform development, expansion of the company's compliance and member advocacy teams, and broader adoption among federal government contractors nationwide. CVRD modernizes benefits compliance for contractors under the Service Contract Act, Davis-Bacon Related Acts, and prevailing wage laws, pairing real-time benefit tracking with an Individual Coverage Health Reimbursement Arrangement (ICHR) and dedicated member advocates. ([Link](#))

Healthcare Weekly News and Deals – May 25th, 2026

4. [Kin Health raises \\$9M Seed led by Maveron with participation from Town Hall Ventures, Flex Capital, Eniac Ventures, The Family Fund, Pear VC, Watershed Ventures, Foundry Square Capital, and angel investors including GoodRx co-founders Doug Hirsch and Trevor Bezdek, Nabeel Quryshi, Jay Desai, Alex Cohen, and Saharsh Patel.](#)

Los Angeles-based Kin Health, a free patient-facing app that records and summarizes medical visits, has raised a \$9 million Seed round led by Maveron. Participation came from Town Hall Ventures, Flex Capital, Eniac Ventures, The Family Fund, Pear VC, Watershed Ventures, Foundry Square Capital, and a deep angel roster including GoodRx co-founders Doug Hirsch and Trevor Bezdek (who join as founding partners and executive chairmen), Nabeel Quryshi, Jay Desai, Alex Cohen, Saharsh Patel, and more than 30 physicians. Funding will expand the consumer product, deepen Kin's longitudinal health-record capability, build a clinical quality engine, and develop downstream care navigation features. [\(Link\)](#)

5. [Nourish raises \\$100M Series C led by Menlo Ventures with participation from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners.](#)

New York-based Nourish, the largest dietitian-led metabolic health clinic in the U.S., has closed a \$100 million Series C at a reported \$1.75 billion post-money valuation, taking total funding to \$215 million. Menlo Ventures led the round, with partner J.P. Sanday joining the board, alongside Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners. Capital will grow Nourish's network of 10,000-plus registered dietitians, accelerate AI-agent investment for patients and providers, expand its metabolic clinic care model with GLP-1 integration, and deepen partnerships with health plans, employers, and health systems. [\(Link\)](#)

6. [Vi \(Vi Labs\) completes a \\$145M transaction at a \\$1.64B valuation with shareholders including General Atlantic, Revelstoke, 1902 Capital \(managed by The Pritzker Organization\), Square Peg, Savano Capital, and Island Green.](#)

New York-based Vi, the enterprise-AI platform for healthcare, life sciences, and wellness, has completed a \$145 million transaction valuing the company at \$1.64 billion alongside the launch of a new suite of vertically specialized AI agents. The transaction consisted of both secondary and primary capital, supporting top talent retention and acquisition, platform and new product investment, and balance sheet strengthening. The company's shareholders include General Atlantic, Revelstoke, 1902 Capital managed by The Pritzker Organization, Square Peg, Savano Capital, Island Green and others. Vi serves 100-plus enterprise customers, supports more than 190 million lives, and has helped bring 50-plus drugs to market. [\(Link\)](#)

7. [cAMPfield Therapeutics Raises \\$180M Series A to Advance I&I Pipeline](#)

cAMPfield Therapeutics, a San Diego-based inflammation and immunology (I&I) company led by former Roivant executive Bill Gerhart, has closed a \$180 million Series A financing. The round was led by Mountainfield Venture Partners with strong participation from a marquee syndicate including Novo Holdings, RA Capital, Frazier Life Sciences, Deep Track Capital, Forbion, Abingworth, Venrock, and Longitude Capital. Proceeds will be used to advance cAMPfield's pipeline of licensed assets targeting autoimmune and inflammatory diseases, as well as support clinical development and business development activities. The substantial raise reflects continued strong investor appetite for high-quality I&I platforms in a competitive therapeutics landscape. [\(Link\)](#)

Healthcare Weekly News and Deals – May 25th, 2026

8. Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology

Blank Bio has closed a Seed financing round and entered a strategic collaboration with PacBio. The partnership combines Blank Bio's AI expertise with PacBio's long-read sequencing technology to develop advanced RNA foundation models for precision oncology. The collaboration aims to improve the discovery and development of novel RNA-based therapeutics and biomarkers by generating higher-resolution transcriptomic insights. This marks another significant step in the convergence of AI and long-read sequencing for next-generation cancer therapies. [\(Link\)](#)

9. Vital Signals raises over \$15M led by XYZ Ventures to transform blood pressure management.

San Francisco-based Vital Signals, founded by technology veteran Tom Moss, has raised more than \$15 million in funding led by XYZ Ventures to advance its consumer blood pressure and long-term cardiovascular health platform. XYZ Ventures' Ross Fubini described the company as having achieved a "technological breakthrough previously assumed to be impossible." Proceeds will support product development and commercialization of its consumer-facing monitoring platform ahead of a planned Series A of \$50–100 million. Moss previously held leadership roles at Google, Motorola, Razer, and Skydio. The funding addresses hypertension, which affects more than 100 million Americans and is often called the "silent killer." [\(Link\)](#)